Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a major epidemic threat since the beginning of 2020. Efforts to combat the virus and the associated coronavirus disease 2019 (COVID-19) disease are being undertaken worldwide. To facilitate the research on the virus itself, a number of surrogate systems have been developed. Here, we report the efficient production of SARS-CoV-2 virus-like particles (VLPs) in insect cells. Contrary to widely used pseudovirus particles, where only one coronaviral protein is displayed within a heterologous scaffold, developed VLPs are structurally similar to the native virus and allow for more throughput studies on the biology of the infection. On the other hand, being devoid of the viral genome, VLPs are unable to replicate and thus safe to work with. Importantly, this is the first report showing that SARS-CoV-2 VLPs can be efficiently produced in insect cells and purified using scalable affinity chromatography.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565087PMC
http://dx.doi.org/10.3389/fmicb.2021.732998DOI Listing

Publication Analysis

Top Keywords

insect cells
12
severe acute
8
acute respiratory
8
respiratory syndrome
8
syndrome coronavirus
8
virus-like particles
8
functional severe
4
coronavirus virus-like
4
particles insect
4
cells severe
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!